echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > What are the limitations of China's new drug development system exposed in the new crown epidemic?

    What are the limitations of China's new drug development system exposed in the new crown epidemic?

    • Last Update: 2020-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At this stage, pinning so much hope on Redcieway reflects the failure, not the success, of our new drug development systemIt is a classic example of why we need a new model of drug development that is not limited by the current market economy model to respond to epidemicoutbreaks and other neglected infectious diseases (Neglected Infectious Diseases, NID)Since 2002, such as Severe Acute Respiratory Syndrome (SARS) (2002-2003), Swine Flu (H1N1) (2009-2010), Middle East Respiratory Syndrome (MERS) (2015, 2016, 20 18), The Zika virus (2015-2016), the Ebola virus (2014, 2017, 2018, 2019) and other epidemics have caused nearly 600,000 deaths around the world, the world has invested a lot of human and material resources to treat, prevent and recoverHowever, in the wake of these devastating outbreaks, the pharmaceutical industry has been unable to insist on investment in new treatments and related vaccines, despite clear warnings from academia, business and others that another pandemic is likelySo, in late 2019, the Covid-19 caught people off guardfrom the Covid-19 pandemic, the pharmaceutical industry is responding to a full response to save people from global catastrophesAbbott's new coronavirus rapid detection technology has won him enthusiastic acclaim, and after decades of profiteering from the opioid crisis, Johnson and Johnson has even aired an eight-episode reality show to boost its campaign for a new corona vaccine research projectBut this is not a situation for an industry that has long known that another pandemic could occur but has only now made meaningful investments in researchthis may surprise the general public, investment in pandemic preparedness and NIDs such as tuberculosis and malaria is not, and has never been, a priority for drug companies, in today's capital-driven market, even though these diseases cause more than 2 million deaths a year, almost seven times as many as covid-19 deaths so farThere are several reasonsthe disconnect between public health needs and pharmaceutical market behaviourOne is that outbreaks are unpredictable and may sometimes not last long enough to create enough markets for a new treatment, and that diseases such as malaria and Ebola are mainly affecting poor people in low-income areas such as Africa, which do not constitute a lucrative marketinvest in new treatments to address potential pandemic threats, or buy back shares to boost share prices and generate more revenue? Drug makers are likely to choose the latter, just as there are common rules in other industries - higher shareholder profits, executive pay, rather than investing in new products, services or employees2018, global funding for NID research and drug development will be only $4 billion, of which 64 percent comes from public taxes, 19 percent from charitable organizations, pharmaceutical companies contribute only 17 percent, or $650 million, and combined with the concept of global TOP20 pharmaceutical companies with total revenues of more than $612 billion in 2018, and $650 million in real drug companies contributing to global pharmaceutical companiesIn fact, the limitations of pharmaceutical industry investment are not limited to NIDs and pandemic preventionEarlier this year, WHO issued a report saying that the fight against drug-resistant infections was being weakened by falling investment and a lack of innovation in new antibiotic researchThe continued withdrawal of large pharmaceutical companies from this area, driven mainly by small and medium-sized enterprises, has led to a serious shortage of research and development of new antibiotics Most of the 50 antibiotics currently in clinical trials are limited to existing antibiotics, while only two are resistant to gram-negative bacteria with multiple resistance In addition, these products are still in the early stages of development, the most optimistic situation is only about 10 years to have 2-5 products on the market pandemic, NID, drug-resistant infections, and so on, are already pressing for global health crises, the truth is that many pharmaceutical companies are more inclined to spend time researching how to keep the patent period for existing drugs longer than those that are really important to human health, for example, by filing hundreds of patents for a drug under the guise of pharmaceutical innovation to prevent generics from dividing the market and thus continuing to drive up drug prices in an analysis of patent applications for 12 of the best-selling drugs in the United States, researchers noted that, on average, there were 125 patent applications and 71 patents granted for each drug; The model of drug development, which is mainly restricted by market economy orientation, clearly does not apply to the response to the human public health crisis If we are prepared to take this seriously and prepare seriously for potential future epidemics, NIDs, drug-resistant infections, and so on, we need a new economic model of drug development that does not rely on market privileges First, we need to conduct existing research in a more open and transparent manner, even if some of it is protected by intellectual property The pharmaceutical industry is sitting on numerous patents and research developments, but unless there are opportunities in the market, many of them will be difficult to continue, and a more open scientific platform could earlier stimulate broader research engagement, saving time and deepening drug research , for example, the company recently announced that it is exploring the development of an oral or inhaled form of Ridsiewe to replace the intravenous infusions that currently have to be performed in hospitals, and that if Gilead can cooperate earlier and more widely, scientists could explore the feasibility of drug delivery forms earlier, making drug use easier and easier for the poor to access second, there should be no over-reliance on the "private" part of the PPP The current situation is that the government invests heavily in hospitals, enterprises and other to pay for the research and treatment of new coronary pneumonia, but in the end, these knowledge, research results may enter the public health-oriented private pharmaceutical enterprises Therefore, it is a feasible strategy to invest more, build the scientific research ability and transformation ability of "public" and turn basic research into practical final drugs to solve the urgent public health problems that may be faced Maybe before the next big pop, we can start preparing in addition, the rapid expansion of intellectual property awareness around the world over the past 40 years has led to a prolonged market monopoly and the increasing privatization of scientific research in the pharmaceutical industry, and perhaps the exploration of new intellectual property systems that are more suitable for modern drug market competition and new drug research and development (original title: Limitations of the drug market model exposed by the new crown outbreak)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.